Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Czechia

Research and Innovation Action · Running

BEATsep Biomarkers established to stratify sepsis long-term adverse effects to improve patients’ health and quality of life

Coordinator
Fakultni Nemocnice U Sv Anny V Brne, Czechia
Runs
1 January 2024 to 31 December 2028
Status
Running
EU funding
€6.9m
Total cost
€6.9m
Partners
11 organisations in 6 countries
Type
Research and Innovation Action
Grant agreement
101137484

What the project is doing

In the project's own words, from its summary on CORDIS.

Sepsis is a life-threatening organ dysfunction resulting from dysregulated immune responses to infection, affecting almost 50 million people yearly. Sepsis is a major global health challenge and a leading cause of death worldwide. Moreover, people surviving sepsis often suffer post-sepsis immunosuppression, a long-lasting state of immune dysfunction predisposing them to infections, autoimmune and non-communicable diseases (NCDs), and long-term reduced fitness.

The molecular mechanisms driving post-sepsis immunosuppression remain largely elusive. Furthermore, predicting which patients will survive or develop immunosuppression is currently impossible. BEATsep will tackle this challenge by combining the expertise of physicians, clinician scientists and immunologists in top European institutions. We will, for the first time, longitudinally assess unique immunological and clinical parameters and combine them to: i) gain insight into the long-term immunological consequences of septic shock; ii) identify novel markers to identify patients at risk; and iii) unravel molecular mechanisms driving post-sepsis immunosuppression.

We will also develop strategies to improve the stratification of acute sepsis survivors to identify patients with a higher risk of sepsis-associated NCDs and comorbidities. BEATsep will have significant societal, scientific, and economic impacts, as efficient prevention of sepsis-induced comorbidities could save significant amounts within healthcare budgets and potentially improve the quality of life for millions worldwide who suffer from the long-term effects of sepsis.

Topics

Who is involved

OrganisationCityCountryRole
Fakultni Nemocnice U Sv Anny V BrneBrnoCzechiaCoordinator
Ludwig Boltzmann Gesellschaft Osterreichische Vereinigung Zur Forderung Der Wissenschaftlichen ForschungWienAustriaParticipant
Fakultni Nemocnice BrnoBrnoCzechiaAssociatedpartner
Masarykova univerzitaBrnoCzechiaParticipant
Statni Zdravotni UstavPraha 10CzechiaParticipant
Biovariance GmbHTirschenreuthGermanyParticipant
Universitatsklinikum BonnBonnGermanyParticipant
Centre Hospitalier Regional De Marseille Assistance Publique-Hopitaux MarseilleMarseille Cedex 20FranceParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
University of GalwayGalwayIrelandParticipant
Univerzita Komenskeho V BratislaveBratislava 1SlovakiaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI